NCT01645332 - Efficacy and Safety of DLBS3233 in Subjects With New Onset of Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

104

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

September 30, 2014

Conditions

Type-2-diabetes MellitusNew Onset

Interventions

DRUG

Placebo of DLBS3233

Placebo of DLBS3233 once daily for 12 weeks

DRUG

DLBS3233

100 mg DLBS3233 once daily for 12 weeks

OTHER

Lifestyle modification

Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.

Trial Locations (1)

50231

Division of Endocrinology, Department of Internal Medicine, Dr. Kariadi Hospital, Semarang